Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance.

Camgoz A, Gencer EB, Ural AU, Baran Y.

Leuk Lymphoma. 2013 Jun;54(6):1279-87. doi: 10.3109/10428194.2012.737919. Epub 2012 Nov 20.

PMID:
23098068
[PubMed - indexed for MEDLINE]
2.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Lee J, Shen P, Zhang G, Wu X, Zhang X.

Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017. Epub 2012 Nov 19.

PMID:
23201011
[PubMed - indexed for MEDLINE]
3.

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.

Cancer Res. 2008 Dec 1;68(23):9809-16. doi: 10.1158/0008-5472.CAN-08-1008.

PMID:
19047160
[PubMed - indexed for MEDLINE]
Free Article
4.

Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells.

Camgoz A, Gencer EB, Ural AU, Avcu F, Baran Y.

Leuk Lymphoma. 2011 Aug;52(8):1574-84. doi: 10.3109/10428194.2011.568653.

PMID:
21756066
[PubMed - indexed for MEDLINE]
5.

Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.

Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T.

Int J Cancer. 2008 Jun 1;122(11):2621-7. doi: 10.1002/ijc.23435.

PMID:
18338755
[PubMed - indexed for MEDLINE]
6.

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP.

Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30.

PMID:
21718141
[PubMed - indexed for MEDLINE]
7.

Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.

Ekiz HA, Can G, Gunduz U, Baran Y.

Hematology. 2010 Feb;15(1):33-8. doi: 10.1179/102453310X12583347009775.

PMID:
20132660
[PubMed - indexed for MEDLINE]
8.

Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.

Kim JE, Yoon S, Choi BR, Kim KP, Cho YH, Jung W, Kim DW, Oh S, Kim DE.

Leukemia. 2013 Aug;27(8):1650-8. doi: 10.1038/leu.2013.60. Epub 2013 Feb 25.

PMID:
23434731
[PubMed - indexed for MEDLINE]
10.

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A.

J Clin Oncol. 2009 Sep 1;27(25):4204-10. doi: 10.1200/JCO.2009.21.8230. Epub 2009 Aug 3.

PMID:
19652056
[PubMed - indexed for MEDLINE]
Free Article
11.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.

Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.

PMID:
20145140
[PubMed - indexed for MEDLINE]
Free Article
12.

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.

Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM.

Blood. 2011 Aug 25;118(8):2211-21. doi: 10.1182/blood-2010-10-313692. Epub 2011 Jul 5.

PMID:
21730355
[PubMed - indexed for MEDLINE]
Free Article
13.

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.

La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A.

Haematologica. 2008 May;93(5):765-9. doi: 10.3324/haematol.12186. Epub 2008 Mar 26.

PMID:
18367481
[PubMed - indexed for MEDLINE]
Free Article
14.

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.

Oncotarget. 2012 Dec;3(12):1557-65.

PMID:
23238683
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T.

PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8.

PMID:
23409026
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.

Airiau K, Mahon FX, Josselin M, Jeanneteau M, Belloc F.

Cell Death Dis. 2013 Oct 3;4:e827. doi: 10.1038/cddis.2013.309.

PMID:
24091670
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.

Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P.

J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.

PMID:
22089930
[PubMed - indexed for MEDLINE]
18.

[K562 cell line resistance to nilotinib induced in vitro and preliminary investigation of its mechanisms].

Wang JS, Yang C, Fang Q, Wei SX, Chen C, Yang Y, Wang YT, Hu XY, Ma D.

Zhonghua Xue Ye Xue Za Zhi. 2012 Nov;33(11):906-10. Chinese.

PMID:
23363745
[PubMed - indexed for MEDLINE]
Free Article
19.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

PMID:
23044928
[PubMed - indexed for MEDLINE]
20.

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.

J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27.

PMID:
23446755
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk